login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

Serotonin levels can be detected and measured through an innovative device called WINCS


Monday, 07 Feb 2011 14:31

Mayo Clinic researchers have concluded that, through deep brain stimulation, a Wireless Instantaneous Neurotransmitter Concentration System (WINCS) can detect and measure serotonin levels in the brain. The findings suggest that in the future such measurements of serotonin may help establish a therapeutic mechanism of deep brain stimulation for psychiatric disease. This study was published in the September 2010 issue of the Journal of Neurosurgery.


Serotonin is a neurotransmitter in the brain that is thought to play a key role in controlling depression, the second most disabling condition in the developed world, with lifetime prevalence in the United States of 17%. Using deep brain stimulation, neurosurgeons can help patients with essential tremor, Parkinson’s disease, movement disorders, and now, based on this study, psychiatric disorders.


“In a previous study, in order to better understand the mechanism of deep brain stimulation, we created WINCS, a new device that successfully measured such neurotransmitter levels as dopamine and norepinephrine on a second-by-second basis,” said Kendall Lee, neurosurgeon at Mayo Clinic. “In this experiment, we wanted to try to measure serotonin, which is very important in the mechanism of depression and its treatment. This study shows that WINCS can measure serotonin with a technology called fast-scan cyclic voltammetry, which is an electrochemical method of being able to measure serotonin in real time in the living brain,” Kendall added.

Researchers collaborated with Mayo Clinic’s division of Engineering and Paul Garris, at Illinois State University, who helped design and test the WINCS device. “We were able to take the laboratory method of neurotransmitter detection and create a miniaturised, wireless, computer-controlled device that allowed the detection to occur in real time,” says Kevin Bennet, chair, Mayo Clinic’s division of Engineering “We took the technique of fast-scan cyclic voltammetry, created real-time control and reporting, and converted it into something that can be used in animals and humans.”

“Using this device, we can now do real-time serotonin measurement, so we are hopeful that in the near future we are able to use WINCS to measure serotonin in the human brain,”  said Lee “What is significant is that if we can measure serotonin, perhaps we can modulate it. This opens the door for even more exciting areas of medicine. By having technology such as WINCS, rather than just diagnosing or measuring neurotransmitters, you can use this as a therapeutic tool to more precisely regulate brain neurotransmitter levels.”




Add New Comment

Most popular


Better outcomes observed in MR CLEAN non-general anaesthesia subgroup in post-hoc analysis
Thursday, 02 Apr 2015
In a post-hoc analysis of the use of general anaesthesia in the MR CLEAN trial (Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands) ... Better outcomes observed in MR CLEAN non-general anaesthesia subgroup in post-hoc analysis

Study suggests feasibility of Baby Trevo for treatment of distal cerebrovascular occlusions
Thursday, 14 May 2015
Diogo Haussen and colleagues (Emory University School of Medicine, Atlanta, USA) report that their initial data suggest that treatment of distal cerebrovascular occlusions with the Trevo XP ProVue 3x2... Study suggests feasibility of Baby Trevo for treatment of distal cerebrovascular occlusions

Evidence builds for endovascular treatment of acute ischaemic stroke
Friday, 17 Apr 2015
With the publication of two more stroke trials, the evidence in favour of endovascular treatment in patients with acute ischaemic stroke has reached new heights. Data from SWIFT PRIME and REVASCAT ... Evidence builds for endovascular treatment of acute ischaemic stroke

Features


New day in acute ischaemic stroke therapy
Friday, 17 Apr 2015
The newest generation of trials for acute ischaemic stroke, including MR CLEAN, ESCAPE, EXTEND IA and SWIFT PRIME, appear to have ushered in a new era in stroke therapy. Now, Joseph Broderick (... New day in acute ischaemic stroke therapy

Flow diverter technology for intracranial aneurysms
Tuesday, 31 Mar 2015
Gabor Toth writes for NeuroNews about the flow diverters that are currently available and the ongoing clinical trials that could have the potential to extend the indications of flow diverter therapy ... Flow diverter technology for intracranial aneurysms

Profiles


Robert E Harbaugh
Thursday, 14 May 2015
Robert E Harbaugh speaks to NeuroNews about how far neurosurgery has come, and as president of AANS ... Robert E Harbaugh

Joseph Broderick
Wednesday, 07 Jan 2015
Joseph Broderick speaks to NeuroNews about the future of neurology and his research, in particular, ... Joseph Broderick

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions